Liver CirrhosisNCT02468479
Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients With Liver Cirrhosis
An observational study of Liver Cirrhosis, run by General Hospital of Shenyang Military Region at 1 site in China.
Trial summary
Chest/abdominal wall varices and spider nevi are two common presenting signs of liver cirrhosis. Their prognostic values remain unclear. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Liver Cirrhosis
- What is being tested?
- No relevant intervention.
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- Jun 2015to Dec 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with a diagnosis of liver cirrhosis who are consecutively admitted to our department.
Who may be able to join
- Liver cirrhosis.
- Consecutive admission.
- Permitted to physical examinations.
- Informed consents.
Who cannot join
- Non-cirrhotic portal hypertension.
- Malignancy.
- Uncontrolled infection.
- Severe chronic diseases.
- Poor patient compliance.
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Gastroenterology, General Hospital of Shenyang Military Area
Shenyang, Liaoning, 110840
About this study
Official title: Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients
Chest/abdominal wall varices and spider nevi are two common presenting signs of liver cirrhosis. Their prognostic values remain unclear.
- Conditions
- Liver Cirrhosis
- Being tested
- No relevant intervention.
- Keywords
- Liver cirrhosis
- Medical subject headings
- Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No relevant intervention.Other
No relevant intervention.
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence and type of chest/abdominal wall varices and spider nevi
Baseline data
Measured: 1.5 years
Association between etiology of liver cirrhosis and type of chest/abdominal wall varices and spider nevi
Baseline data
Measured: 1.5 years
Association between degree of liver function and type of chest/abdominal wall varices and spider nevi
Baseline data
Measured: 1.5 years
Effect of chest/abdominal wall varices and spider nevi on survival
Follow-up data
Measured: 2.5 years or more
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2015 (estimated)
- Study startJun 2015
- Primary completionDec 2016
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Liver CirrhosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- General Hospital of Shenyang Military Region
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xingshun Qi, General Hospital of Shenyang Military Region
- Investigators
- Xiaozhong Guo, MD, PhD, Principal investigator, Department of Gastroenterology, General Hospital of Shenyang Military Area
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02468479
- Sponsor's protocol ID
- CAWV-LC
- Status last verified
- Apr 2017
- First submitted
- 4 Jun 2015
- Last updated
- 19 Apr 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Li H, Wang R, Mendez-Sanchez N, Peng Y, Guo X, Qi X. Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis. Arch Med Sci. 2019 Mar;15(2):434-448. doi: 10.5114/aoms.2018.74788. Epub 2018 Mar 28.
PubMed 30899297
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients
- ClinicalTrials.gov ID
- NCT02468479
- Acronym / sponsor ID
- CAWV-LC
- Conditions
- Liver Cirrhosis
- Keywords
- Liver cirrhosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- General Hospital of Shenyang Military RegionUniversity, hospital or other
- Study start
- Jun 2015
- Primary completion
- Dec 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 10 Jun 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chest/abdominal wall varices and spider nevi are two common presenting signs of liver cirrhosis. Their prognostic values remain unclear.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with a diagnosis of liver cirrhosis who are consecutively admitted to our department.
Key inclusion criteria (4 listed)
- Liver cirrhosis.
- Consecutive admission.
- Permitted to physical examinations.
- Informed consents.
Key exclusion criteria (5 listed)
- Non-cirrhotic portal hypertension.
- Malignancy.
- Uncontrolled infection.
- Severe chronic diseases.
- Poor patient compliance.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No relevant intervention.No relevant intervention. | Other | – |
Primary outcome
Prevalence and type of chest/abdominal wall varices and spider nevi
Time frame: 1.5 years
Baseline data
Association between etiology of liver cirrhosis and type of chest/abdominal wall varices and spider nevi
Time frame: 1.5 years
Baseline data
Association between degree of liver function and type of chest/abdominal wall varices and spider nevi
Time frame: 1.5 years
Baseline data
Effect of chest/abdominal wall varices and spider nevi on survival
Time frame: 2.5 years or more
Follow-up data
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2017.
- Derived from this study: PubMed 30899297Li H, Wang R, Mendez-Sanchez N, Peng Y, Guo X, Qi X. Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis. Arch Med Sci. 2019 Mar;15(2):434-448. doi: 10.5114/aoms.2018.74788. Epub 2018 Mar 28.
Related trials for Liver Cirrhosis
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiaozhong Guo, MD, PhD principal investigator
Department of Gastroenterology, General Hospital of Shenyang Military Area
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cirrhosis, run by General Hospital of Shenyang Military Region at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence and type of chest/abdominal wall varices and spider nevi (time frame: 1.5 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02468479, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2017.